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In the past decade, it became apparent that immune mediated
cell death in a number of autoimmune endocrine diseases was
due to the induction of apoptosis in target organ cells. This was
conclusively demonstrated for thyroid follicular cells in
Hashimoto's (destructive autoimmune) thyroiditis, but the
mechanisms underlying this cell death were not clear. Several
hypotheses were put forth involving the role of death-
signalling molecules expressed on thyroid cells. While many
of these hypotheses did not hold up under close scrutiny, this
stimulated work on the molecular mechanisms of thyroid
destruction. Several apoptosis signalling pathways, initiated by
molecules such as Fas ligand (FASL) and tumour necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL), have
been shown to be active in thyroid cells and may be involved
in destructive thyroiditis. In this review we will attempt to sort
out the inconsistencies in published data on the mechanisms of
death-receptor mediated thyroid destruction. We will also
review recently proposed models of these mechanisms, and
outline directions for research that we feel might lead to
discoveries of benefit to the clinician in the treatment and
prevention of destructive autoimmune thyroiditis.
Autoimmunity-induced hypothyroidism:
an apoptosis-mediated disease
Hashimoto's thyroiditis is a disease characterised by an
immune cell infiltrate, presence of thyroid-specific autoanti-
bodies and thyroid autoantigen-specific T lymphocytes, and
the destruction of follicular structure. While it is often
diagnosed in a euthyroid patient on the basis of goitre and
autoantibodies, over time this usually progresses to a deficit in
thyroid hormone production and the symptoms of hypo-
thyroidism. The most important feature for our discussion is
the destructive nature of this disease and we will refer to this as
`destructive (autoimmune) thyroiditis' to differentiate it from
the other thyroiditis syndromes that do not cause glandular
destruction.
The study of autoimmune thyroiditis has been plagued by
the difficulties in examining a disease that progresses over
long periods of time (Costa et al., 1989; Davies & Amino,
1993; Dayan & Daniels, 1996). The factors that start the
autoimmune destruction are unknown because they occur long
before the diagnosis is made. In addition, the destruction of
thyroid cells occurs slowly, with cell death occurring over
years. While there are other contributing factors such as TSH
receptor blocking antibodies or cytokine inhibition of thyroid
function, that may play a role in thyroid dysfunction, we will
focus on the mechanisms of thyroid follicular cell elimination
as the primary (Dayan & Daniels, 1996) cause of thyroid
hormone deficit in this disease. This thyroid cell elimination is
now known to occur through the process of apoptosis.
While Hashimoto described thyroid destruction in his
initial observations in 1912 (Hashimoto, 1912), only recently
has this cellular destruction been recognized as apoptotic
(Kotani et al., 1995; Okayasu et al., 1995; Tanimoto et al.,
1995). Apoptosis is a mechanism that allows cells to self-
destruct when stimulated by the appropriate trigger. This
process is initiated for various reasons, such as when a cell is
no longer needed within the body or when it becomes a threat
to the health of the organism. The aberrant inhibition or
initiation of apoptosis contributes to many disease processes
(Encyclopñdia Britannica Online,. 2000). It has been calcu-
lated from experiments on animal thyroids and human thyroid
organ cultures that the thyroid gland turns over approximately
5 times during a lifetime (Coclet et al., 1989). Cells must be
continually eliminated to compensate for the production of
new thyroid follicular cells in order to maintain normal thyroid
size and function. Normal thyroid glands show a low level of
apoptosis, suggesting a role for this process in basal thyroid
cell turnover (Dremier et al., 1994; Kotani et al., 1995;
Okayasu et al., 1995; Tanimoto et al., 1995). In contrast
thyroid cells undergoing apoptosis (as determined by immuno-
histochemical and morphological analyses) occur with
increased frequency in thyroids from patients with destructive
thyroiditis (Kotani et al., 1995; Okayasu et al., 1995; Tanimoto
et al., 1995). Many of the apoptotic cells in these glands are
detected in areas of disrupted follicles in proximity to
infiltrating lymphoid cells (Kotani et al., 1995; Hammond
et al., 1997). This suggests that the thyroid destruction in this
disease occurs through thyroid cell apoptosis.
An important point in evaluating the role apoptosis plays in
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mediating destructive thyroiditis is how apoptosis is defined and
detected. At this point it should be noted that some of the
experiments identifying apoptosis in thyroid cells used in situ
(TdT-mediated dUTP Nick-End labelling) TUNEL (ApopTagw)
staining that detects DNA fragmentation through the specific
enzymatic labelling of the 3 0 hydroxyl (OH) group of DNA
molecules. Unfortunately, this technique alone does not
differentiate between apoptosis and necrosis. This method must
be used in conjunction with observation of cell morphology
changes characteristic of apoptosis, and these are sometimes lost
in immunohistochemical staining techniques. The morpho-
logical changes will be described in more detail in the next
section. New, more specific techniques have been developed
which include immunohistochemical detection of protein
epitopes that are unique to cells undergoing apoptosis like
caspase-cleaved Cytokeratin 18 or activated Caspase 3. Thus,
future studies examining this issue should be better able to
measure the extent of apoptosis in the thyroid gland.
Apoptosis: mechanisms and results
Apoptosis is an active, energy dependent cellular process. This
can occur through several different initiating processes including
growth factor deprivation, the toxic actions of radiation and
chemotherapy drugs, and through endogenous molecules that act
as receptors for cell-bound or soluble `death' ligands. These
ligands include tumour necrosis factor (TNF), TNF-related
apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL). While
the activating events start different signal cascades, all of these
communications feed into a final, common apoptosis pathway that
leads to cell death (Strasser et al. 2000). The common pathway
consists of sequential activation of proteases, specifically known
as Caspases. Caspases are cysteine proteases (defined by having a
cysteine residue at their active site) which cleave proteins at
specific peptide sequences that contain an aspartate residue
(Salvesen & Dixit, 1997). These caspases are themselves
activated by specific proteolytic cleavage. This cleavage can be
performed by other caspases, thus amplifying the signal cascade.
The caspase cascade ultimately activates enzymes that progres-
sively digest the cell and its genetic material, producing the classic
morphological changes that occur during apoptosis such as
chromatin condensation, cytoplasmic shrinkage and plasma
membrane blebbing (Wyllie et al., 1980; Wyllie, 1980). Specific
endonuclease cleavage of DNA occurs, and this can be
differentiated biochemically from the random DNA cleavage
that occurs in necrosis because the DNA is cleaved only once for
every turn around chromatin. This leads to a `ladder' effect with
DNA fragments that are multiples of 180 bases (Wyllie, 1980).
Cell destruction proceeds in such a way that it signals engulfment
of the dying cell by surrounding cells, thus preventing the immune
response that occurs with necrotic release of components of
damaged cells (Fadok et al. 2000; Savill & Fadok, 2000). Growth
factor deprivation, radiation and chemotherapeutic agents
initiate apoptosis through the p53 apoptosis pathway signalled
through Apaf-1 and Caspase 9. These events are either enhanced
or inhibited by the Bcl-2 family of proteins that appear to work
in co-ordinated pairs (Strasser et al. 2000). These p53 activation
pathways are not likely to be involved in autoimmune thyroid
apoptosis and will not be discussed here.
In contrast, the apoptosis initiation processes that have
gained so much attention recently are the death receptor-
induced pathways (summarised in Fig. 1). Death receptors are
members of the TNF receptor family of transmembrane
signalling proteins that contain a cytoplasmic protein poly-
merisation domain known as a `death domain' (Baker &
Reddy, 1998; Aravind et al., 1999). The death receptors bind
to and are activated by specific death ligands. Table 1
summarises the known death ligand/receptor interactions.
Receptor-mediated apoptosis can be regulated by controlling
expression of the individual components (usually at the level
of transcription) as well as by endogenous protein inhibitors.
Endogenous inhibitors of receptor-mediated apoptosis include
`decoy' receptors (e.g. DcR1, DcR2, DcR3) (Ashkenazi &
Dixit, 1999) that compete with death receptors for binding of
death ligands and inhibitors of death-induced signalling
complex (DISC) formation or initiators of caspase activation
(e.g. cellular FLICE-like inhibitory protein (cFLIP)) (Irmler
et al., 1997). Caspase inhibitors (e.g. inhibitor of apotosis
protein (IAP) protein family) (Deveraux & Reed, 1999), as
well as inhibitory proteins with as yet undefined mechanisms
(e.g. fas-associated phosphotase-1 (FAP-1) have also been
described (Sato et al., 1995). Regulation of expression of these
molecules appears important for modulating the induction of
apoptosis and provides important clues in designing possible
interventions of the cell death signal (Nicholson, 2000).
Immune-mediated apoptosis
The immune system uses apoptosis to mediate cell-mediated
cytotoxicity of target cells that must be eliminated from an
organism. This has been shown to be important in at least two
specific circumstances where the host's survival is at stake:
(1) elimination of infected (both virus and bacteria) cells and
(2) elimination of neoplastically transformed cells. Another
example of cell-mediated cytotoxicity that is medically
important is allograft rejection. However, if the immune
system eliminates a normal cell that is neither infected nor
transformed (nor foreign), then it is described as autoimmune
destruction and this may result in autoimmune disease. Cell-
mediated cytotoxicity is initiated through two different
mechanisms: (1) effector cell expression of death ligands
presented to target cells and (2) effector cell release of exocytic
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granules containing perforin (which perforates target cell
membranes) and Granzyme B (which initiates apoptosis by
directly activating caspases by proteolytic cleavage (Talanian
et al., 1997; Van de Craen et al., 1997). The first case requires
functional death receptor expression by the target cell. T
lymphocytes and NK cells, both well characterised cytotoxic
cells, have been shown to functionally express the death
ligands TNFa, FasL, and TRAIL when they become activated
(Mariani & Krammer, 1998; Zamai et al., 1998; Kayagaki
et al., 1999).
As mentioned previously, apoptosis is involved in main-
taining a proper balance in cell populations. Apoptosis
eliminates cells in order to maintain a constant number of
cells within a proliferating population, or to eliminate cells no
longer needed. An example of this is following an immune
response when expanded populations of lymphocytes
responding to a perceived threat need to be restrained.
Without reducing the number of these cells an ongoing
inflammatory response could damage normal cells (known as
the `bystander effect'). To reduce the number of these cells,
death ligands on some of the immune cells bind to, and
specifically activate, the death receptors on other immune
cells. The result is that the activated immune cells eliminate
each other by either apoptotic suicide or fratricide. Loss of
the ability to reduce immune cell numbers through this
mechanism results in unregulated expansion (hyperplasia) of
immune cells leading to lymphoproliferative autoimmunity.
Examples of this include a Lupus-like disease of Fas and
FasL deficient mice (Cohen & Eisenberg, 1992) and
Autoimmune Lymphoproliferative Syndrome (ALPS) (Fisher
Fig. 1 Components of the death
receptor-mediated apoptosis signalling
pathway.
Table 1 Death receptor/ligand interactions and decoy receptors
Death receptor Ligand Decoy receptors
Fas (CD95) FasL (CD95L) DcR3, soluble Fas
TNF-RI TNFa, Lymphotoxin soluble TNF-R
Death receptor 3 Apo3L/TWEAK ±
Death receptor 4 TRAIL (Apo2L) DcR1 (TRAIL-R3, TRID, LIT), DcR2(TRAIL-R4,TRUNDD)
Death receptor 5 TRAIL DcR1, DcR2
Death receptor 6 unknown ±
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et al., 1995; Dianzani et al., 1997). The former condition
results in organ-specific autoimmunity, including thyroiditis
and hypothyroidism, in addition to the Lupus-like syndrome
(Green et al., 1995a; Green et al., 1995b). ALPS in humans
has been linked to mutations in Fas, FasL and Caspase 10,
but the autoimmune response is neither organ-specific nor is
it apoptotically destructive of any specific organ. It is
possible that thyroid specific autoimmunity in humans may
be influenced by a similar generalised loss of immune
control, but this has yet to be documented. Support for this
statement comes from the fact that autoimmune thyroiditis is
often associated with other autoimmune diseases such as
diabetes and Addison's disease, possibly suggesting a
common defect predisposing to apoptotic destruction of the
endocrine organs (Baker, 1992).
Inflammatory cytokines have numerous effects on the
immune system including the regulation of apoptosis.
Cytokines such as interferon g (IFNg), interleukin-1 (IL-1)
and TNF can influence immune-mediated apoptosis both
directly and indirectly. Cytokines can regulate expression
levels of apoptosis pathway components and inhibitors in
target cells, as well as regulate effector cell expression of
apoptosis initiators. They can also promote apoptotic activity
in effector cells by promoting growth, migration and activation
of these cells.
Many inflammatory cytokines are present in an inflamed
thyroid. Experimental evidence for a role of these cytokines
in autoimmune thyroid disease has been well-documented
(Kawakami et al., 1990; Frohman et al., 1991; Stull et al.,
1992; Tang et al., 1993; Ajjan et al., 1996; Schuppert et al.,
1996; Alimi et al., 1998). A role for inflammatory cytokines
in the effector phase of destructive thyroiditis may lie in
the regulation of thyroid follicular cell susceptibility to
immune-directed, death receptor-mediated apoptosis. This
information combined with the previously mentioned obser-
vation of infiltrating immune cells adjacent to apoptotic
thyroid follicular cells strongly supports a role for the
participation of immune-mediated apoptosis in the effector
phase of destructive thyroiditis. The molecular mechanisms for
mediating this apoptotic death in the thyroid are currently
being elucidated.
Receptor-mediated apoptosis in thyroid cells
A variety of different models have been proposed to describe
immune cell destruction of thyroid cells. Each of the models
assumes that some sort of an immune response to thyroid
autoantigens occurs and stimulates an immune cell infiltration
into the thyroid gland (initiator phase), and this then leads to
thyroid cell death (effector phase). However, the existence of
inflammatory cell infiltrates in the thyroid does not inevitably
lead to thyroid destruction. There are a number of thyroiditis
syndromes that occur without gland destruction (Davies &
Amino, 1993). The change from non-destructive thyroiditis to
destructive thyroiditis occurs by an unknown mechanism. This
suggests that the thyroid cells may play a role in this process
(Volpe, 1994). Because of this it is most important to identify
the molecular signalling of apoptotic destruction in the thyroid
gland during thyroiditis.
In 1997, Giordano and colleagues suggested that thyroid
cells were killing themselves by coexpressing Fas and FasL
under conditions found in an inflamed thyroid (Giordano et al.,
1997). Their hypothesis was based on data that showed
constitutive expression of FasL on thyroid follicular cells from
goitre and thyroiditis tissue (Giordano et al., 1997), while Fas
appeared to be expressed only in thyroids from destructive
thyroiditis patients. These investigators also showed data
suggesting that IL-1b, an inflammatory cytokine found in
abundance in thyroiditis, could induce functional expression of
Fas in thyroid cells in culture (Giordano et al., 1997). They
concluded that the constitutively expressed FasL in the
thyroid could induce apoptosis in thyroid cells that are exposed
to IL-1b provided by the infiltrating immune cells. However,
this intriguing hypothesis (Williams, 1997) was inadvertently
based on data that had major technical flaws. In a rare
convergence of bad fortune, the investigators used two
commercial antibodies marketed as being specific for FasL.
However, these antibodies were later proven to give false
positive results in western blot analysis (Fiedler et al., 1998;
Baker & Bretz, 2000; Fiedler & Eibel, 2000), flow cytometry
(Smith et al., 1998) and immunohistochemistry (Strater et al.
2000). In addition, they used a reverse transcriptase poly-
merase chain reaction (RT-PCR) analysis of Fas and FasL that
appeared to be flawed (Stokes et al., 1998) and used goiterous
cells as a `normal control' (Stokes et al., 1998). In a follow-up
technical commentary, the authors demonstrated that other
FasL specific antibodies also detected FasL in thyroid cells.
However, these antibodies also have been shown to be
inadequate for FasL detection (Strater et al. 2000)1. Immuno-
histochemical staining of normal thyroid was presented which
1 Strater et al. (2000) have demonstrated that of 12 commercially
available antibodies tested for immunohistochemical staining, 3
showed false positive results (clone 33, C-20, N-20; overestimated
FasL expression), 8 showed false negative results (NOK-1, NOK-2,
4H9, MIKE-1, MIKE-2, 8B8, A11, 4A5) and only one (G247-4 from
Pharmingen) accurately reflected expression as demonstrated by in situ
hybridization detection of FasL mRNA. Although Strater et al. (2000)
Temp. only address the specificity of these antibodies in immunohis-
tochemical staining, this data combined with the previously published
problems concerning antibodies used for FasL detection by other
methods, make it critical that FasL expression be carefully evaluated
using multiple antibodies that have demonstrated reliability that is
confirmed by mRNA detection techniques.
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the authors described as FasL, however, these follicular cells
have atypical thyroid follicle morphology (Papoff et al., 1998).
Others have used different antibodies to demonstrate FasL
expression in the thyroid in Graves' disease (Hiromatsu et al.,
1999b) and papillary thyroid cancer (Mitsiades et al. 2000a),
but their results are also confounded by the use of antibodies
that either give false positive or false negative results (Strater
et al. 2000)1. The antibodies that specifically detect FasL
expression did demonstrate expression in the thyroid (Hir-
omatsu et al., 1999b; Mitsiades et al. 2000a) but the relative
levels of expression are difficult to evaluate due to the
antibody's unreliability (Strater et al. 2000). In fact Mirakian
et al. (1998), in a non-peer-reviewed commentary, stated that
their group found that contrary to prior reports Hashimoto's
thyroiditis-derived cells expressed less FasL than Graves'
thyroid follicles, but the antibody they employed for this
analysis was not reported. Inducible Fas expression in thyroid
cells has recently been confirmed by another group (Kawakami
et al., 1996), but this data was contradicted by the majority of
publications which showed constitutive Fas expression by
normal thyroid cells (Tanimoto et al., 1995; Arscott et al.,
1997; Hammond et al., 1997). In summary, FasL expression
occurs in the thyroid under some pathogenic conditions, but
the correlation between expression and disease pathogenesis
remains to be demonstrated.
In trying to examine function of the Fas pathway in thyroid
cells, several unique observations have been made. Functional
Fas expression has been reported in normal thyroid cells
(Arscott et al., 1997; Bretz et al., 1999b), papillary thyroid
cancer cells (Arscott et al., 1999), and thyroid cancer cell lines
(Mitsiades et al. 2000a). However, function was only
demonstrated when the cells were treated with the protein
synthesis inhibitor cycloheximide or with inflammatory
cytokines (Kawakami et al., 1996; Arscott et al., 1997; Bretz
et al., 1999; Paolieri et al., 1999). This demonstrates that
although Fas protein is expressed on thyroid cells the pathway is
regulated and inhibited under normal conditions. The optimal
condition for the induction of Fas-mediated apoptosis in thyroid
cells requires pretreatment with IFNg and TNFa (Bretz et al.,
1999b). Whereas untreated cells are totally resistant to FasL,
apoptosis is detectable in cytokine pretreated cells within 2 h
and is nearly completed within 7 h of Fas-activation (Bretz et al.,
1999b). Reports on Fas-mediated thyroid cell death under other
conditions required significantly longer, non-physiologic time
periods (Kawakami et al., 1996; Giordano et al., 1997;
Kawakami et al., 1997), calling into question whether the death
was truly the result of Fas-mediated apoptosis.
Additional recent publications also seem to argue against
Fas-mediated thyroid suicide (as proposed by Giordano et al.,
1997). Mice genetically manipulated to specifically over-
express FasL in the thyroid do not have increased apoptosis in
thyroid cells (Batteux et al. 1999, Batteux et al. 2000). When
immune cell infiltrates are induced in these mice by injection
with thyroid autoantigen, there was a reduction in inflamma-
tion in mice expressing the transgene as compared to control
animals (Batteux et al. 2000; Batteux et al., 1999b). Mitsiades
et al. 2000b recently described evidence that the thyroid
inhibitor drug methimazole can induce FasL expression in
thyroid cells. They propose the hypothesis that the methima-
zole-induced FasL contributes to the immunomodulatory effect
of this drug by killing infiltrating lymphocytes, but not thyroid
cells where Fas pathway function is inhibited. This data also
argues against the theory that FasL is constitutively expressed
on thyrocytes. Soluble Fas expression has been reported in
Graves' disease, and is even observable in the serum of
individuals with this disorder (Shimaoka et al., 1998;
Hiromatsu et al., 1999a). There does not appear to be toxic
effect from this level of soluble FasL as there is no evidence of
hepatocyte apoptosis in these patients. However, a potential
role for soluble FasL could exist in Graves' disease given the
reports of complications, such as liver and cardiac dysfunction,
that occur in this disorder. In summary, it is unlikely that
thyroid cells kill themselves through self-expressed FasL/Fas
interaction. While FasL or Fas most likely both exist on the
thyroid and are functional under unique conditions, no
experimental data proving a causal relationship between Fas
and autoimmune thyroid disease has been produced. In
contrast, there appears to be some data supporting anti-
inflammatory and immune surveillance roles for the Fas
pathway in thyroid disease. Given the data produced by
Giordano et al. (1997) Dayan and colleagues proposed that the
FasL expression by thyrocytes could be combined with their
ability to express MHC class II proteins after exposure to
cytokines (Dayan et al. 1997). This would allow the thyrocytes
to eliminate Fas-expressing thyroid antigen-specific (autoreac-
tive) T lymphocytes that would bind the thyroid cell expressed
MHC class II antigens through the T cell receptor. This is
bolstered by evidence that shows inflammatory cytokines can
also upregulate cell adhesion molecules like ICAM and LFA
that can tighten the cell-to-cell contact thus increasing
interactions that could lead to induction of apoptosis (Paolieri
et al., 1999). Several groups have shown thyroid cells
functionally capable of killing Fas-susceptible cells (Giordano
et al., 1997; Hiromatsu et al., 1999b; Mitsiades et al., 1999;
Mitsiades et al. 2000b) and Fas expressing lymphocytes are
present in thyroid infiltrates (Hammond et al., 1997; Stassi
et al., 1999). A report documenting the reduction of immune
infiltration by transgenic expression of thyroid cell FasL in the
mouse experimental autoimmune thyroiditis (EAT) model
supports this concept (Batteux et al. 2000). A defect in the
ability to fight off immune cells would lead to thyroid
destruction.
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The conventional model of immune-mediated thyroid
destruction asserts that antigen-specific cytotoxic immune
cells destroy thyroid cells. Thyroid-derived and peripheral
blood lymphocytes, when activated, have been shown to be
cytotoxic to thyroid cells (Creemers et al., 1983; Sack et al.,
1986; MacKenzie et al., 1987; Kawakami et al. 2000).
However, this activity may be a normal function for
eliminating neoplastically transformed cells known as
`immune surveillance'. The presence of FasL expressing
lymphocytes in destructive thyroiditis also supports this model
(Mitsiades et al., 1998). Several groups have argued against
this model because they found very low levels of FasL
expression by infiltrating cells (Mitsiades et al., 1998; Stassi
et al., 1999). Again, this data was complicated by the use
of antibodies that underestimate FasL expression by immuno-
histochemical staining (Strater et al. 2000)1. Flow cytometry
data in one of these papers showed 12% of the infiltrating
T lymphocytes were FasL positive which is arguably a
significant percentage for inducing apoptosis in thyroid cells
(Stassi et al., 1999). One group has published in a non-peer-
reviewed article that a proteinase commonly used in tissue
preparation can inhibit FasL activity (Palazzo et al. 2000).
Preparation of tissues with this proteinase may digest FasL and
cause underestimation of its expression. This may account for
the low expression levels in thyroid infiltrating lymphocytes as
determined by flow cytometry. It would appear that the
mechanisms are in place for thyroid cells and thyroid-
infiltrating immune cells to either `kill or be killed'. The
results would be destructive autoimmunity in one extreme or
progression of a thyroid neoplasm in the other. It may be the
careful balance between these outcomes that is required for the
health of the thyroid. We can conclude from the data cited
above and below that the combinations of inflammatory
cytokines present in the thyroid microenvironment have an
important role in this balance. We have reviewed this in more
detail previously (Bretz & Baker, 2000).
The `TRAIL' leading to thyroid destruction
We have recently generated data to support an alternative or
perhaps complimentary model of death-receptor-mediated
apoptotic destruction of thyroid follicular cells. TRAIL is a
death ligand with significant homology to FasL. TRAIL acts
through its receptors, Death Receptor 4 and Death Receptor 5,
to induce apoptosis. We have demonstrated expression of these
death receptors on thyroid follicular cells by RNase protection
assay (Bretz et al., 1999a), western analysis and immuno-
histochemical staining (Bretz et al., unpublished data), each by
two different antibodies. We also showed regulation of these
receptors by inflammatory cytokines and increased expression
in destructive thyroiditis (Bretz et al, unpublished data).
Recombinant TRAIL is capable of killing thyroid cells
(presumably through Death Receptor 4 and/or Death Receptor
5) only after cycloheximide treatment suggesting the existence
of a labile inhibitor. Pretreatment with the unique combination
of TNFa and IL-1b, demonstrating that the inhibitor is not the
same as that postulated for the Fas pathway (Bretz et al.,
1999b; Bretz et al., unpublished data). Interestingly, we have
also demonstrated inflammatory cytokine induced functional
expression of TRAIL by thyroid cells (Bretz et al., 1999a).
Expression of TRAIL is strongest after treatment of the cells
with IFNg in combination with TNFa or IL-1b. Intriguingly,
these are the best conditions for Fas-mediated death of these
cells (Bretz et al., 1999b), but they are different from the
conditions for TRAIL-induced killing (Bretz et al., unpub-
lished data). Cells expressing TRAIL were capable of killing a
TRAIL-susceptible lymphoid cell line and a TRAIL-neutralis-
ing antibody blocked this activity (Bretz et al., unpublished
data). Immunohistochemical staining of normal thyroid tissue
also showed TRAIL expression and this staining was increased
in thyroid follicles undergoing destruction in tissue derived
from patients with destructive thyroiditis (Bretz et al.,
unpublished data). TRAIL is known to be expressed by
activated lymphocytes and capable of effecting cell-mediated
cytotoxicity. We also showed that TRAIL mRNA is expressed
in thyroid-infiltrating lymphocytes (Bretz et al., 1999a).
The information above can be applied to constructing
models for the involvement of TRAIL in destructive
thyroiditis similar to the FasL models. These models have
been outlined previously (Bretz et al., 1999a; Bretz & Baker,
2000) and are summarised schematically in Fig. 2. In brief,
the above mentioned data supports the hypotheses that
TRAIL may be involved in thyroid follicle destruction by
immune cells expressing TRAIL, or alternatively TRAIL may
be involved in a defence mechanism for the thyroid cells to
resist immune cell attack. In support of the later model it has
been shown that TRAIL death receptors are expressed on
autoreactive immune cells (Wendling et al. 2000). Also, it is
possible that inflammatory cytokine induced TRAIL, when it
interacts with cytokine activated TRAIL death receptors on
the same thyroid cell, would lead to cell suicide or fratricide.
This scenario is unlikely due to the fact that different
cytokine combinations are required for these two activities
(TRAIL induction by IFNg/TNFa and TRAIL susceptibility
by TNFa/IL-1b). The combination of all three cytokines
inhibits TRAIL-induced killing (Bretz et al., unpublished
data). It is possible that a defect in these signals could lead to
thyroid cell suicide. The switch that regulates whether TRAIL
expression results in killing of thyroid cells or intrathyroidal
lymphocytes is probably the presence of IFNg. IFNg protects
thyroid cells from TRAIL-mediated apoptosis and also
provides a key signal for the induction of TRAIL by those
6 J. D. Bretz and J. R. Baker Jr
q 2001 Blackwell Science Ltd, Clinical Endocrinology, 55, 1±11
same thyroid cells. IFNg also plays a role in activation of T
lymphocytes which can result in their susceptibility to
TRAIL. In the absence of IFNg the thyroid cells may
become susceptible to TRAIL and do not express any TRAIL
for their defence. As previously mentioned, it is noteworthy
that IFNg also appears to be a key ingredient in providing a
signal that makes thyroid cells susceptible to FasL-induced
apoptosis.
There is also evidence to support the notion that TRAIL is
more likely than FasL to be involved in thyroid gland
destruction. TRAIL killing is specific for thyroid epithelial
cells (Bretz et al., unpublished data) while Fas-mediated
killing also occurs in thyroid-derived fibroblasts and vascular
smooth muscle cells treated with the same inflammatory
cytokine combinations that promote thyroid cell death (Bretz,
unpublished data). Apoptosis of fibroblasts or vascular smooth
muscle cells has not been reported in thyroiditis. In fact
fibrosis is common in destructive thyroiditis. It is obvious that
more data is needed to definitively support any of these
models. The pattern of cytokine regulation of TRAIL
expression by, and specific TRAIL-induced killing of thyroid
cells provides a more plausible model for its role in destructive
thyroiditis than the Fas pathway. Although this data does not
exclude a role for apoptosis induction through other death
receptors in destructive thyroiditis, we believe that the data
supports the investigation of TRAIL receptor-mediated
Fig. 2 Potential models for the involvement
of TRAIL in autoimmune destructive thyroi-
ditis. (a) The combination of inflammatory
cytokines TNFa and IL-1b, produced by
activated immune cells, induce thyroid cell
susceptibility to TRAIL. Immune cells
expressing TRAIL can subsequently kill the
thyroid cells. Killing would be restricted to
thyroid cells by activation of thyroid specific
T lymphocytes that were presented thyroid
autoantigens. (b) The combination of inflam-
matory cytokines IFNg and TNFa, produced
by activated immune cells, induce TRAIL
expression by thyroid cells. Immune cells
that have become activated by thyroid auto-
antigen presentation are susceptible to
TRAIL and only thyroid autoantigen-specific
immune cells will be killed. If the thyroid
cells are cancerous then the tumour may use
this mechanism to defend against immune
attack, a process known as `immune eva-
sion'. (c) Cytokine induction of both thyroid
expression of TRAIL (by IFNg combined
with TNFa) and thyroid susceptibility to
TRAIL (by TNFa combined with IL-1b)
would lead to the thyroid cell killing itself.
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apoptosis as deserving an equal consideration for further study
in this area of research.
Lack of evidence of a role for Bcl-2 in destructive
thyroiditis
Bcl-2 is the prototype member of a family of protein regulators
of apoptosis signalling (Reed, 1997; Adams & Cory, 1998;
Green & Reed, 1998; Newton & Strasser, 1998; Strasser et al.
2000). It has been proposed that regulation of Bcl-2 or
members of the Bcl-2 family may be involved in destructive
thyroiditis (Palazzo et al. 2000). This hypothesis is based on the
observation that Bcl-2 expression, as detected by immuno-
histochemical staining, is decreased in thyroid follicular cells
in destructive thyroiditis when compared to follicles from
normal thyroid tissue (Hammond et al., 1997; Mitsiades et al.,
1998). Also, in non-peer-reviewed data, one group has argued
that Bcl-x, a Bcl-2 homologue, is regulated by inflammatory
cytokines in thyroid cells (Palazzo et al. 2000). The only
mechanistic data to support this was the finding that antisense
nucleic acid inhibition of Bcl-2 in a thyroid cancer cell line
could enhance Fas-mediated apoptosis (Fujieda et al., 1998).
A careful review of the literature does not support this
hypothesis. Other groups have not found the same correlation
between reduced Bcl-2 expression and destructive thyroiditis
(Okayasu et al., 1995) (Branet et al., 1996). But regardless of
this observation it is unlikely that Bcl-2 plays a significant role
in destructive thyroiditis for several reasons. Kawakami et al.
(1996) showed no change in Bcl-2 expression in cultured
normal thyroid cells that became susceptible to Fas-mediated
apoptosis after inflammatory cytokine treatment. Elimination
of Bcl-2 would be expected to result in spontaneous thyroid
cell destruction but there have been no reports of thyroid
abnormalities in Bcl-2 gene knockout mice (or in transgenic
mice over expressing Bcl-2). The most compelling argument
against a role for Bcl-2 in destructive thyroiditis is that recent
findings suggest that Bcl-2, and other Bcl-2 family members,
are not directly involved in regulating the apoptotic signal by
death receptors prior to the point of signal irreversibility, but
are only involved in regulating the amplification of the death
signal (Strasser et al., 1995; Keogh et al. 2000; Strasser et al.
2000). Bcl-2 does not block death receptor signals; it only
slows down the signal by inhibiting the amplification of that
signal. Yet Bcl-2 is capable of inhibiting apoptosis initiated by
other mechanisms such as stress signals like DNA damage,
growth factor deprivation and treatment with corticosteroids
(Strasser et al. 2000). These are unlikely to play a role in the
effector phase of destructive autoimmune thyroiditis.
To further clarify this issue, several experiments in animal
models should be employed. Over-expression of Bcl-2 could
be accomplished in primary thyroid cells in culture or in
transgenic mice and the Bcl-2 gene could be knocked out
in mice specifically in the thyroid. These tools should be
used to determine whether there is a role for Bcl-2 in death
receptor-mediated apoptosis of these cells.
What's next? Outline for the future.
The evidence that we have reviewed is strongly suggestive of a
role for death receptor-mediated apoptosis in destructive
autoimmune thyroiditis. But the data has largely been
produced in vitro or in situ, and is mostly just correlative.
For this information to be translated into information to be
used in clinical practice more definitive proof is required to
first determine the precise mechanisms of thyroid apoptosis
in vivo, and second to link this activity to destructive
thyroiditis. To achieve this aim transgenic, gene knockout or
Cre/LoxP (organ-specific targeted gene knockout) mice might
be used in mouse thyroiditis models to determine the specific
role of genes implicated in thyroid cell apoptosis (FasL, Fas,
TRAIL, Death Receptor 4, Death Receptor 5, decoy receptors).
It has been postulated that a number of genes may contribute
to an individual's susceptibility to autoimmune thyroiditis and
that it is the total accumulation of some (but not necessarily all
or any specific combination) of these genetic alterations
combined with environmental factors that lead to disease.
Although genetic defects in apoptosis-related pathways could
produce a generalized problem, it is likely that thyroid-specific
autoimmunity is initiated by genetic and environmental factors
that cause thyroiditis, and apoptotic defects would then
facilitate thyroid destruction. This concept is bolstered by the
fact that many forms of thyroiditis do not result in thyroid
destruction. Also, in animal models of autoimmunity, inflam-
matory phases can be mechanistically separated from target
organ destruction (Kolb, 1997; Pilstrom et al., 1997; Dilts &
Lafferty, 1999; Ohsako & Elkon, 1999; Pakala et al., 1999).
Analysis attempting to link specific apoptotic genes to the
development of destructive thyroiditis may be useful in
understanding pathogenesis of these disorders. In this regard,
several apoptosis signalling genes have been mapped to
chromosomal regions genetically linked to autoimmune
thyroid disease (Tomer et al., 1999). More precise genetic
mapping, using the tools provided by the Human Genome
Project, should clarify potential roles for these genes and may
facilitate identification of genetically susceptible individuals
for preventative therapies.
The differential regulation of the FasL and TRAIL pathways
by inflammatory cytokines suggests the various apoptosis
signalling mechanisms are controlled by distinct molecular
mechanisms. We have postulated the existence of a labile
inhibitor for each of these pathways (Arscott et al., 1997; Bretz
et al., 1999a). It will be important to identify these inhibitors
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and other regulatory molecules. This information might make
it possible to design specific pharmaceutical interventions to
restrain autoimmune thyroid destruction. Several agents that
regulate apoptosis in vitro are currently being tested in
preclinical and clinical trials and could potentially be available
to the clinician in a few years (Nicholson, 2000). Hopefully,
this will allow the interesting information developed on
apoptosis to be translated into medical practice.
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